HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $15

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Unicycive Therapeutics (NASDAQ: UNCY ) with a Buy and lowers the price target from $22 to $15.